CL2022002466A1 - Agonista del receptor de glp-1, composición farmacéutica, y método de preparación - Google Patents

Agonista del receptor de glp-1, composición farmacéutica, y método de preparación

Info

Publication number
CL2022002466A1
CL2022002466A1 CL2022002466A CL2022002466A CL2022002466A1 CL 2022002466 A1 CL2022002466 A1 CL 2022002466A1 CL 2022002466 A CL2022002466 A CL 2022002466A CL 2022002466 A CL2022002466 A CL 2022002466A CL 2022002466 A1 CL2022002466 A1 CL 2022002466A1
Authority
CL
Chile
Prior art keywords
same
pharmaceutical composition
glp
receptor agonist
preparing
Prior art date
Application number
CL2022002466A
Other languages
English (en)
Inventor
Young Kwan Kim
Mín Mí Jo
Jun Park
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210034452A external-priority patent/KR102563111B1/ko
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2022002466A1 publication Critical patent/CL2022002466A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel compound useful as an agent for treatment or prophylaxis of various metabolic diseases such as obesity or diabetes and hyperlipidemia, by means of excellent GLP-1 agonist activity and an excellent DMPK profile, an isomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method for preparing the compound.
CL2022002466A 2020-03-18 2022-09-09 Agonista del receptor de glp-1, composición farmacéutica, y método de preparación CL2022002466A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200033477 2020-03-18
KR1020210034452A KR102563111B1 (ko) 2020-03-18 2021-03-17 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법

Publications (1)

Publication Number Publication Date
CL2022002466A1 true CL2022002466A1 (es) 2023-03-03

Family

ID=77771773

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002466A CL2022002466A1 (es) 2020-03-18 2022-09-09 Agonista del receptor de glp-1, composición farmacéutica, y método de preparación

Country Status (14)

Country Link
US (1) US20230203021A1 (es)
JP (1) JP2023520181A (es)
AU (1) AU2021237185B2 (es)
BR (1) BR112022018646A2 (es)
CA (1) CA3171173A1 (es)
CL (1) CL2022002466A1 (es)
CO (1) CO2022014271A2 (es)
IL (1) IL296336A (es)
JO (1) JOP20220213A1 (es)
MX (1) MX2022011349A (es)
PE (1) PE20230175A1 (es)
TW (1) TWI825398B (es)
WO (1) WO2021187886A1 (es)
ZA (1) ZA202210199B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CR20220178A (es) 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
MX2023001311A (es) 2020-08-06 2023-04-18 Gasherbrum Bio Inc Agonistas heterociclicos de glp-1.
CN116406360A (zh) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 杂环glp-1激动剂
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
JP2024514259A (ja) * 2021-04-08 2024-03-29 エルジー・ケム・リミテッド Ｇｌｐ－１受容体作動薬、それを含む薬学的組成物、およびその製造方法
KR20230173708A (ko) 2021-04-21 2023-12-27 길리애드 사이언시즈, 인코포레이티드 카르복시-벤즈이미다졸 glp-1r 조절 화합물
WO2022246019A1 (en) 2021-05-20 2022-11-24 Eli Lilly And Company Macrocyclic glucagon-like peptide 1 receptor agonists
CN118215478A (zh) 2021-09-08 2024-06-18 盐野义制药株式会社 用于预防和治疗与抗肥胖作用有关的疾病的药物
CN116574092A (zh) * 2022-05-20 2023-08-11 成都地奥九泓制药厂 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用
WO2024063140A1 (ja) * 2022-09-22 2024-03-28 塩野義製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を有する単環化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221404B (zh) * 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
KR20140107340A (ko) * 2011-12-12 2014-09-04 레셉토스, 인코포레이티드 당뇨병과 같은 치료를 위한 glp-1 수용체 조절제로서 작용하는 4 개의 사이클을 포함하는 카르복실산 유도체
PE20191501A1 (es) * 2016-12-16 2019-10-22 Pfizer Agonistas receptores de glp-1 y sus usos de los mismos
JP7249950B2 (ja) * 2017-03-27 2023-03-31 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ヘテロ環化合物
PT3806855T (pt) * 2018-06-15 2023-05-03 Pfizer Agonistas dos receptores de glp-1 e suas utilizações
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CR20220178A (es) * 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
US20230051318A1 (en) * 2019-12-02 2023-02-16 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist

Also Published As

Publication number Publication date
JP2023520181A (ja) 2023-05-16
PE20230175A1 (es) 2023-02-01
TWI825398B (zh) 2023-12-11
US20230203021A1 (en) 2023-06-29
ZA202210199B (en) 2023-06-28
CO2022014271A2 (es) 2022-10-21
TW202200559A (zh) 2022-01-01
CA3171173A1 (en) 2021-09-23
IL296336A (en) 2022-11-01
MX2022011349A (es) 2022-11-10
JOP20220213A1 (ar) 2023-01-30
AU2021237185B2 (en) 2023-11-30
WO2021187886A1 (ko) 2021-09-23
AU2021237185A1 (en) 2022-10-06
BR112022018646A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
CL2022002466A1 (es) Agonista del receptor de glp-1, composición farmacéutica, y método de preparación
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
MX2021006908A (es) Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
NZ721645A (en) Compounds for use as gpr120 agonists
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
PH12016502034A1 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
PH12019550154A1 (en) Azetidine derivative
BR112017021631A2 (pt) composto, composição farmacêutica, combinação farmacêutica, método de tratamento, uso de um composto e processo para preparação de dito composto
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
UA107702C2 (en) Novel benzamide derivatives
BR112021019779A2 (pt) Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo
ATE418553T1 (de) Histamin-h3-rezeptor inhibitoren, ihre herstellung und therapeutische anwendungen
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
NZ766972A (en) Compounds having s1p5 receptor agonistic activity